Adults diagnosed with stage-1 skin, prostate or breast cancer have the same chance of still being alive a year later as the general population, data from the Office for National Statistics and Public Health England suggests.
For many cancers, one-year survival rates are high if they are diagnosed in stages 1-3, but lower in stage 4.
Pancreatic cancer has the lowest rates of survival, for men and women.
The estimates are based on cancer diagnoses in England from 2012-16.
Oxford Biodynamics PLC (LON:OBD) was spun out from Oxford University in June 2007 with the aim of translating fundamental scientific advances into a commercialised platform technology and a new generation of biomarkers for cancer and other diseases including ALS.